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| INTRODUCTION
The introduction of oral direct inhibitors of factor Xa or thrombin has greatly improved medical care and safety in the prevention and treatment of thrombotic disorders. However, bleeding remains a concern, particularly in patients with risk factors such as advancing age, anemia, and renal disease. 1 As such, there remains a medical need for new agents with an improved safety profile and equivalent or superior efficacy compared with existing therapies.
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Factor XI (FXI) is the zymogen form of activated coagulation factor XI (FXIa). Inhibition of FXI or FXIa has potential as a novel anticoagulant therapeutic target because it is thought to block the amplification or propagation of the intrinsic coagulation pathway while leaving the extrinsic (tissue factor) pathway and the common pathway intact. Thus, the intrinsic pathway is inhibited to an extent that is sufficient to prevent thrombosis while the hemostatic response is maintained. [2] [3] [4] Several lines of preclinical and clinical evidence support FXI inhibition as an antithrombotic strategy that may potentially be associated with a lower risk of bleeding than existing therapies.
Epidemiological studies have shown that, compared with the general population, the risk of venous thromboembolism (VTE) and stroke is lower in individuals with FXI deficiency and higher in those with elevated FXI levels. [5] [6] [7] [8] [9] [10] [11] In preclinical studies, genetically altered FXI knockout mice or animals treated with pharmacological FXI/ FXIa inhibitors were protected from venous and arterial thrombosis without an observed increased risk of bleeding. 3, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Furthermore, in a phase 2 proof-of-concept study in patients undergoing total knee replacement, reduction in FXI levels following administration of an antisense oligonucleotide was associated with a reduced risk of VTE and a numerically lower rate of bleeding events compared with treatment with enoxaparin.
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BAY 1213790 is a fully human immunoglobulin (Ig)G1 monoclonal antibody (mAb) that was generated using phage display
technology. Crystal structure analysis demonstrated a novel allosteric mechanism of action of BAY 1213790, which bound to a region adjacent to the FXIa active site, leading to substantial structural rearrangements (Schaefer et al., unpublished data).
The objectives of this study (EudraCT number: 2014-003816-35) were to evaluate the safety, pharmacodynamics, and pharmacokinetics of intravenously administered BAY 1213790 in healthy male volunteers.
| METHODS

| Study population
Healthy Caucasian male volunteers aged 18-55 years with a body mass index (BMI) in the range 18-30 kg/m 2 were eligible for inclusion. Key exclusion criteria were: known coagulation disorders or conditions that increase bleeding risk; known severe allergies; hypersensitivity to study drug or excipients; use of medication that may have an impact on the study objectives; the presence of relevant disease in the 4 weeks preceding the study; and a history of smoking more than five cigarettes per day or suspicion of drug/alcohol abuse.
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and in compliance with the
International Conference on Harmonization guidelines for Good
Clinical Practice. All relevant study documents were approved by the local ethics committee, and volunteers provided written informed consent.
| Study design
In this phase 1, single-center, randomized, single-blind, parallelgroup, placebo-controlled, dose-escalation study, eligible volunteers were sequentially assigned by an independent group to a unique randomization number in ascending order and randomized 4:1 to receive a single dose of BAY 1213790 or placebo (isotone sodium chloride solution, 0.9%) as a 60-minute intravenous infusion (40 mL).
Bioanalysis and evaluation of adverse events were performed in nonblinded fashion.
Study drug was administered on day 1. Volunteers were admitted to the study site 1 day before drug administration and discharged on day 7. Nine doses (0.015, 0.06, 0.15, 0.3, 0.6, 1.25, 2.5, 5, or 10 mg/kg) of BAY 1213790 were studied, with a planned sample size of 10 volunteers per dose cohort (eight receiving BAY 1213790 and two receiving placebo). Dose escalation was performed on approximately a monthly basis, only after acceptable safety and tolerability had been established during days 1-7 of the previous dose step.
Follow-up procedures were performed on days 14, 21, 28, and 56 (±3 days), with an optional visit at day 84, for all dose steps. Owing to a longer-than-expected elimination half-life (t ½ ) of BAY 1213790, the visit at day 84 subsequently became mandatory, along with an additional follow-up visit at day 150 (±7 days), for dose steps of 1.25 mg/ kg or higher.
Essentials
• BAY 1213790, a fully human IgG1 monoclonal antibody, inhibits activated coagulation factor XI.
• In this phase 1 study in healthy men, BAY 1213790 exhibited favorable safety and tolerability.
• BAY 1213790 dose-dependently increased clotting time without observed effects on bleeding risk.
• Further evaluation of BAY 1213790 in patients with, or at risk of thrombosis, is warranted. 
| Safety
| Pharmacodynamics
| Pharmacokinetics
Blood samples for pharmacokinetic analysis were taken predose, at 
| Statistical analyses
No formal sample size calculation was performed for this exploratory study. The maximum ratio to baseline in aPTT and the minimum ratio to baseline in apparent FXI activity were compared for each active treatment group vs placebo by using an exact Wilcoxon ranksum test, at the one-sided significance level of α = 0.05. Tests were performed in sequential order (i.e, if all previous null hypotheses for a specific endpoint had been rejected, the next null hypothesis was tested) starting with the highest dose. For placebo, data from the different dose steps were pooled. Hodges-Lehmann estimates of the shift from placebo were determined, together with the associated two-sided 90% CIs.
The following pharmacokinetic parameters were analyzed assuming log-normally distributed data:
C max /D and C max, norm . An exploratory analysis of variance (ANOVA) including the factor treatment was performed on log-transformed values of these parameters to investigate dose proportionality.
Statistical test results were not adjusted for multiplicity and were considered exploratory. There was no imputation for missing data. Analyses were performed using SAS software, version 9.2 (SAS Institute, Inc., Cary, NC).
| RESULTS
| Volunteer disposition and demography
In total, 83 healthy Caucasian men were randomized to receive BAY 1213790 or placebo; of these, 81 received study medication (Table 1) . A total of 78 volunteers completed the study (Figure 1 ).
| Safety
All 81 patients who received study medication were included in the safetyanalysis set ( Treatment-emergent AEs with a possible relationship to study drug administration were reported in six volunteers (7.4%) ( Table 2) 
| Pharmacodynamics
The pharmacodynamic analysis set included data from 80 volunteers.
Data from the volunteer whose infusion was terminated owing to AEs were not included.
| aPTT
Dose-dependent increases in aPTT were observed following BAY 1213790 administration ( Figure 2A and B) ; the increase vs placebo was significant for all doses except the lowest dose studied (0.015 mg/kg) (Table S1) 
| FXI activity
There was a dose-dependent reduction in apparent FXI activity from baseline following BAY 1213790 administration (Figure 3 ). For doses of 0.15 mg/kg or higher, the reduction in FXI activity was significant vs placebo (Table S2) 
| Bleeding time
Bleeding times did not increase following BAY 1213790 administration and were similar across all study dose cohorts, including placebo, during the first 6 days following drug administration (Figure 4 ). 
| ROTEM whole blood clotting time
| Biomarkers of thrombosis
Levels of D-dimer, TAT, and F1.2 did not significantly increase from baseline following administration and, throughout the study, were similar to levels measured in volunteers who received placebo ( Figure   S2 ). Overall there were no signs of procoagulant activity following BAY 1213790 administration.
| Pharmacokinetics
The pharmacokinetic analysis included data from 66 volunteers who received BAY 1213790. There was a dose-dependent in- (Table S4 ).
| DISCUSSION
This first-in-human, phase 1, dose-escalation study demonstrated that single intravenous doses of the fully human IgG1 mAb, One volunteer in the BAY 1213790 0.6 mg/kg group who did not complete the study owing to an AE completed follow-up; one volunteer who completed the study was lost to follow-up. AE, adverse event; PD, pharmacodynamics; PK, pharmacokinetics There were no signs of spontaneous, prolonged, or hidden bleeding following BAY 1213790 administration. BAY 1213790 is a fully human mAb, and accordingly the incidence of infusion reaction in the present study was low (1.2%). In addition, no clinically relevant antidrug antibody formation was observed. Infusion-related reactions, ranging in severity from mild to severe, have been observed following administration of mAbs and can occur at the first or following repeated exposure. 23 The risk of these reactions is lower with fully human mAbs than with humanized or chimeric mAbs; for example, the incidence of infusion reactions has been reported as 4% for the fully human mAb panitumumab compared with 77% for rituximab, a human/mouse chimeric mAb. 24, 25 Moreover, nontherapeutic, neutralizing antidrug antibodies can develop after mAb administration and bind epitopes needed for biological activity, which can potentially alter the pharmacokinetics, safety, and/or efficacy of the mAb. 23 Fully human antibodies, such as BAY 1213790, are associated with a lower risk of such immune responses in humans than mouse or chimeric antibodies. (20) 1 (14) 3 (43) 1 (14) 3 (50) 2 (25) 4 (50) 1 (13) 1 (13) 1 (14) Treatment-related AEs, n ( Data are presented as geometric mean (% coefficient of variation) unless stated otherwise. AUC, area under the plasma concentration-time curve; AUC (0−tlast) , AUC from time 0 to the time of the last measured plasma concentration greater than the lower limit of quantification; CL, total body clearance; C max , maximum plasma drug concentration; t ½ , elimination half-life; t max , time to reach maximum plasma concentration; V ss , apparent volume of distribution at steady state. a Only one volunteer in the lowest dose group (0.015 mg/kg) had measurable plasma concentrations of BAY 1213790, so summary statistics were not 
